Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958080 | 0.95 | PTPN1 (0.45) | PTPN1PTPN2PTPRBPTPN6PTPN11 | |
| SCHEMBL4958087 | 0.88 | PTPN1 (0.40) | PTPN1PTPN2PTPRBPTPN6PTPN11 | |
| SCHEMBL6154059 | 0.85 | PTGES (0.40) | PTGESALOX5GAALPAR1LPAR5 | |
| SCHEMBL4955383 | 0.83 | PTPN1 (0.43) | PTPN1PTPN2S1PR1 | |
| SCHEMBL5506735 | 0.83 | PTPN1 (0.43) | PTPN1PTPN2PTPRBPTPN6PTPN11 | |
| SCHEMBL6155070 | 0.81 | PTPN5 (0.45) | PTPN1PTPN2PTPRBPTPN6PTPN11 | |
| SCHEMBL4958895 | 0.78 | PTGES (0.57) | S1PR1PTGESALOX5LPAR1LPAR5 | |
| SCHEMBL5502775 | 0.75 | PTPN1 (0.44) | PTPN1PTPN2PTPRBPTPN6PTPN11 | |
| SCHEMBL4956777 | 0.75 | PTPN1 (0.41) | PTPN1PTPN2PTGESALOX5 | |
| SCHEMBL4955386 | 0.75 | NR3C1 (0.39) | PTGESALOX5GAALPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | PTPN1 15/4885PTPN2 18/4885PTPRB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.